Novartis flu vaccine suspended following deaths in Italy

By Dan Stanton contact

- Last updated on GMT

Italy's AIFA is investigating to lots of Novartis' Fluad
Italy's AIFA is investigating to lots of Novartis' Fluad

Related tags: Influenza vaccine, Influenza, Vaccine, Flu vaccine

Italy has suspended the use of Fluad despite Novartis saying no causal relationship has been established between its seasonal flu vaccine and three deaths.

The Italian Medicines Agency (AIFA) announced yesterday it was recalling two lots and suspending the use of the Swiss Biopharma’s seasonal flu vaccine after reports that three people died and one suffered severe adverse effects soon after being injected with a dose of Fluad.

The agency is awaiting the outcome of an investigation of lots 142701 and 143301 of Fluad but said in a statement it was banning the use “as a precautionary measure.”

In a statement sent to Biopharma-Reporter.com, Novartis said it had been notified by AIFA of the suspension adding “no causal relationship to the vaccine has been established.

“Patient safety is our first priority and we take these reports very seriously. A review of the two batches has confirmed that they are in conformity with all production and quality standards. Novartis is working closely with AIFA for further assessment.”

Since its approval in 1997, the firm says the product has a “robust safety history”​ with over 65 million doses of the trivalent, surface antigen, inactivated influenza virus vaccine have been administered worldwide. Despite this, the vaccine was temporarily banned by AIFA in 2012​ after tests found a batch contained protein particles.

Fluad Manufacture

Last month​ Novartis agreed to sell its flu vaccine division to CSL Limited for $275m (€216m), which includes three manufacturing sites in Holly Springs, North Carolina, Liverpool, UK, and Marburg, Germany, with the deal is likely to go through in mid-2015.

Fluad is made by growing individual influenza virus strains in the allantoic cavity of embryonated hens’ eggs. These are then harvested and clarified separately by centrifugation and filtration prior to inactivation with formaldehyde.

The inactivated virus is then concentrated and purified by zonal centrifugation, before removing most of the internal proteins by centrifugation in the presence of cetyltrimethylammonium bromide (CTAB).

Fluad is adjuvanted with MF59, an immunologic adjuvant that uses squalene. According to Novartis, this gives a superior antibody response, as compared to conventional vaccines by offering varying degrees of cross-protection.

Related topics: Markets & Regulations, Cell lines

Related news

Show more

Related products

show more

rAAV Production in BioBLU® Single-Use Vessels

rAAV Production in BioBLU® Single-Use Vessels

Eppendorf for Bioprocess – Solutions that grow with you | 25-Jun-2019 | Application Note

Rising interest in gene therapy-based applications leads to increasing demands in scalable production systems for viral vectors. Find out how Cevec Pharmaceuticals...

Small-Scale Cell Culture Perfusion Process

Small-Scale Cell Culture Perfusion Process

Eppendorf for Bioprocess – Solutions that grow with you | 29-Mar-2019 | Application Note

Perfusion cell culture processes promise advantages for industrial bioprocessing, like saving space, increasing volumetric productivity, achieving more...

Cultivation of 3D Cell Aggregates in Perfusion

Cultivation of 3D Cell Aggregates in Perfusion

Eppendorf for Bioprocess – Solutions that grow with you | 17-Sep-2018 | Application Note

3D cell aggregates are of great interest for applications like disease modeling and manufacturing of stem cell-based products. Read more about the cultivation...

Nifty Biosimilar

Nifty Biosimilar

UGA Biopharma | 13-Mar-2018 | Research Study

Aflibercept (Zaltrap®) is a recombinant fusion protein with complex post-translational modifications. Therefore deep understanding of biosimilar development...

Related suppliers

Follow us

Products

View more

Webinars